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CHRONIC RENAL FAILURE AFTER TRANSPLANTATION
How should the immunosuppressive regimen be managed in
patients with established chronic allograft failure?
GABRIEL M. DANOVITCH
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The transplant literature is replete with recommenda- reasonable to suggest that manipulation of immunosup-
tions regarding the choice of immunosuppressive medi- pression will make the kidney from a 65-year-old hyper-
cations for the prevention and treatment of acute rejec- tensive victim of a cerebrovascular event that suffered
tion, and, with somewhat less conviction, for long-term delayed graft function will perform as well as a kidney
maintenance immunosuppression [1]. The question posed from a 20-year-old trauma victim that functioned imme-
in the title, however, has been given minimal attention. diately. Much of the long-term behavior of a graft can
It is of great practical importance, and it is one of the be predicted by its pretransplant features and its early
most frequent questions posed to me by my nephrology post-transplant function without relating to the specifics
colleagues responsible for the long-term care transplant of the immunosuppressive cocktail [7].
of recipients. The discussion that follows will relate prin-
cipally to the immunosuppressive management of the fail-
QUESTIONS TO ADDRESS BEFOREing kidney transplant. The broader diagnostic and man-
MANIPULATING IMMUNOSUPPRESSIONagement issues have been reviewed extensively elsewhere.
The question of adjusting the immunosuppressive reg-
imen for patients with chronic allograft dysfunction mayCHRONIC REJECTION OR CHRONIC
often be the first that is asked of me by my colleagues,ALLOGRAFT NEHROPATHY?
but it is not necessarily the best question to ask. Chronic
Semantics are important since the words we choose allograft failure is essentially a specialized form of chronic
to describe a clinical problem may influence the manner renal failure and should be approached with a similar
in which we try to address it. The clinical syndrome is philosophy. Pre-renal and post-renal reversible causes
familiar: Starting months to years after transplantation, must be ruled out, the volume status must be optimized,
an initially stable patient begins to develop progressive and the medication regimen critically assessed. In most
loss of renal function reflected by a rising serum cre- patients, the diagnosis will be confirmed by biopsy which
atinine and associated with hypertension and varying also serves to uncover the cases of recurrent or de novo
degrees of proteinuria [2]. If an allograft biopsy is per- glomerulonephritis that may account for up to 5% of long-
formed irreversible structural changes are found, including term graft losses. A biopsy also permits a diagnosis of
glomerulosclerosis, interstitial fibrosis and atrophy, and less common but critical-to-diagnose causes of graft fail-
vascular hyalinosis. There may also be patchy interstitial ure such as post-transplant lymphoma and polyoma virus
infiltrates and evidence of calcineurin inhibitor (CI) tox-
nephropathy [8]. Recent changes in immunosuppressive
icity [3]. The clinical course is often unpredictable [4].
drug formulations (e.g., from Sandimmune cyclosporine
The term “chronic rejection” suggests that the alloim-
to Neoral cyclosporine) may cause graft dysfunction, asmune etiology of the process is primary and hence may
may the addition to the medication regimen of drugsbe susceptible to immunosuppressive therapy. The term
that interact with the hepatic metabolism of the CIs [9].“chronic allograft nephropathy” (CAN) may be less sat-
isfying to the purist. but it at least reflects the multiple
factors, both ostensibly immune [5] and non-immune [6], WHAT IS THE APPROPRIATE DOSE OF THE
that have been shown to predict the syndrome. It is un- CALCINEURIN-INHIBITOR IN ESTABLISHED
CHRONIC ALLOGRAFT FAILURE?
Despite nearly 20 years of clinical experience with cy-Key words: immunosuppression, chronic allograft failure, calcineurin-
inhibitor, transplantation. closporine and 10 years with tacrolimus there are still a
paucity of prospective clinical trials comparing various 2002 by the International Society of Nephrology
S-68
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dose regimens of these drugs for long-term use in well- episodes designated as acute rejection that were typically
mild or borderline and responsive to a short course offunctioning grafts, let alone in poorly functioning grafts.
Most of the standard recommendations for well-func- high-dose steroids. No patient was deemed to require
reintroduction or escalation of the CI dose. In a follow-tioning grafts are based on retrospective analyses. There
is also a considerable, though disputed, body of evidence up analysis of this data, the authors concluded that cyclo-
sporine withdrawal was the most beneficial policy forthat it may be safe to discontinue these drugs completely
in many patients, though most practitioners seem to have the management of CAN (abstract A4816, ASN/ISN
World Congress of Nephrology, October 2001). It shoulddetermined that the risk/benefit analysis favors their con-
tinuation [1]. The nephrotoxic potential of the CIs is well be emphasized. however, that the various treatment
groups varied in their baseline characteristics and wereestablished and, although their use is conducive to excel-
lent long-term function, some degree of renal dysfunction, not prospectively randomized, and that only 13 patients
were totally withdrawn from CI drugs. Graetz et al (ab-both reversible and irreversible, is an inevitable conse-
quence of their administration [7]. In the case of CAN, stract A4663, ASN/ISN World Congress of Nephrology,
October 2001) replaced cyclosporine with MMF in athe situation is particularly paradoxical. Is it logical to
continue these drugs, both vasoconstrictors, in the face group of 15 patients with CAN and reported a significant
improvement in the serum creatinine level without graftof fibrosis and vascular hyalinosis for which they may be
in varying degrees responsible? On the other hand, should loss or episodes of acute rejection. Similar findings were
reported by Filler et al [12] in a small group of pediatrictheir use be intensified to address any undertreated allo-
immune response that the histologic picture may sug- patients with progressive graft dysfunction ascribed to
cyclosporine toxicity.gest? A theoretical argument could be made for both
dose reduction and intensification. Based on this data, CI dose reduction in CAN appears
to be safe and well tolerated and to have a beneficialThere is no substantive evidence to suggest that CAN
will respond favorably to intensification of CI dosage, effect on the rate of deterioration of graft function in
to exchanging CIs, or to changing formulations of CIs. a high percentage of patients. Not all patients benefit,
On the contrary, each of these manipulations may be however, and the occurrence of episodes of acute rejec-
followed by apparent transient or permanent deteriora- tion indicates that careful follow-up is mandatory. It is
tion of function, presumably as a result of exaggeration also important to note, as emphasized by Kreis et al [13]
of vasocontriction and nephrotoxity [9]. There is, how- that functional stability or improvement as judged by
ever, a body of evidence suggesting that reduction or the serum creatinine level may not necessarily parallel
discontinuation of these drugs may be beneficial and, in histologic stability.
this regard, the studies of Weir et al [10, 11] are worthy
of particular attention. Starting in 1996, Weir et al [10]
MYCOPHENOLATE MOFETIL FORbegan a policy of reducing the CI dose in patients with
CHRONIC REJECTIONdeclining renal function and biopsy proven CAN. So-
MMF was introduced into clinical transplantationcalled immunosuppressive “support” was maintained by
based on its capacity to reduce the incidence of acuteaddition of mycophenolate mofetil (MMF) or by increas-
rejection in the early post-transplant period [1]. Thereing its dose. Early observations demonstrated a short-
were also theoretical reasons, based on studies in animalterm benefit in the rate of loss of renal function the
models [14], to anticipate that the drug might serve toauthors suggested was caused by a release of CI induced
prevent or treat clinical CAN. Convincing proof of abilityvasoconstriction. The long-term impact of this policy was
to do so, however, has proved elusive, though the avail-then evaluated in a cohort of 118 patients followed over
able data is suggestive. In the prospective studies ofa period of approximately 2 years [11]. Once again, MMF
prophylactic MMF use there was a small but not statisti-was continued or added together with low-dose steroids.
cally significant reduction in the rate of graft loss [15].The decision to discontinue the CI rather than reduce
It should be noted, however, that the studies were notits dose (typically to approximately 50% of its initial
designed or statistically powered to address long-termvalue) was made in only 18 patients in somewhat arbi-
function [1, 15]. In a large retrospective study, Ojo et altrary manner based on HLA matching and the degree
[16] showed that use of MMF at some time during theof renal dysfunction. Depending on the technique used
post-transplant course was associated with a lower inci-to determine the rate of change of renal function follow-
dence of chronic rejection, but the extent of MMF treat-ing the change in CI dose, more than 90% of the discon-
ment to achieve this effect could not be determined.tinued group and 40% of the reduced group showed an
None of these studies, however, address the issue ofimprovement or at least a lack of deterioration in the
whether MMF has a favorable impact on establishedrate of decay of renal function. Thirty-three of the pa-
CAN. In a small, randomized study by Glicklich et altients were biopsied during follow-up to evaluate epi-
sodes of graft dysfunction and there were a total of 19 [17], no benefit could be shown for the addition of MMF
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in a group of patients with established CAN on a stable a CI. Eight of the patients, however, developed pneumo-
nitis. Fischereder et al (abstract A4642, ASN/ISN Worlddose of cyclosporine. On the contrary, Maria et al (ab-
stract A4921, ASN/ISN World Congress of Nephrology, Congress of Nephrology, October 2001) safely converted
12 patients with impaired graft function from cyclospo-October 2001), in a non-randomized study of 18 patients
found that the addition of MMF to a stable or reduced rine to rapamycin and reported improved graft function
without adverse side effects. Macaulay et al (abstractdose of cyclosporine led to a stabilization of graft func-
tion. In the previously discussed studies of Weir et al A4755, ASN/ISN World Congress of Nephrology, Octo-
ber 2001) reported that 10 patients with CAN showed[10, 11], it is not clear whether the addition of MMF
for immunosuppressive “support” played a part in the improvement of graft function after conversion from a
beneficial effect of reduction of the CI dose. To answer CI to rapamycin. However, Saunders et al (abstract 432,
this important question, the study would need to be Transplant 2000 Meeting, May 2000) in a study of 30
repeated with randomization to groups receiving or not patients with CAN found no benefit in adding rapamycin
receiving MMF. Until these data are available, it would to a reduced dose of cyclosporine. In this study, rapa-
seem reasonable to introduce MMF or continue its ad- mycin was introduced while reducing but not discontinu-
ministration if the dose of CI is significantly reduced. ing the CI dose, and it is possible that the potential
benefits of rapamycin were masked by continued CI tox-
icity [18]. Hyperlipidemia may be exaggerated by theRAPAMYCIN FOR CHRONIC REJECTION
addition of rapamycin and may theoretically be a factor
The histology of CAN together with work on experi- in the perpetuation of CAN [24]. It would seem logical
mental models of chronic rejection provide a tempting that if the potential benefits of rapamycin in CAN are to
theoretical rationale for the benefits of rapamycin in be exploited, the drug should be studied in this situation
CAN. These benefits have yet to be proven of clinical together with discontinuation or drastic dose reduction
value [18]. Rapamycin inhibits growth factor mediated of the CI.
proliferation of cells involved in the pathogenesis of
chronic rejection in vitro [19, 20]. In a variety of experi-
MANAGEMENT OF CAN WITH Amental models, rapamycin reduced intimal hyperplasia
FLUCTUATING CREATININE LEVELresulting from both immune and non-immune injury
[18, 21]. The doses of rapamycin used in these studies During the course of CAN, there may be fluctuations
are, however, considerably greater than those used clini- in the serum creatinine level whose clinical significance
cally. Of particular importance rapamycin, in standard may be difficult to assess. Ideally, a full clinical, ultrason-
clinical dosage, has a immunosuppresssive potency ap- ographic, and histologic evaluation would accompany
proaching that of the CIs, but it is not nephrotoxic when each of these events, though patients and physicians may
used alone [18]. be understandably reluctant repeatedly to biopsy pa-
In a large, multicenter, randomized study, the discon- tients with established CAN and empiric decisions may
tinuation of cyclosporine in stable patients with good be required. With respect to the immunosuppression regi-
graft function receiving rapamycin was shown to be safe men, care must be taken to ensure patient adherence,
and to be associated with significant improvement in lack of which could predispose to superimposed acute
graft function [22]. The obvious question, therefore, is rejection episodes. The current availability of multiple,
whether this benefit can be safely reproduced in patients similar but not identical, preparations of cyclosporine
with impaired graft function and, if so, whether any bene- requires that inquiry be made of the patient to determine
fit is transient and likely to be hemodynamic in nature, if a new formulation had been prescribed with a poten-
or long-lasting and likely histologic in nature. Adequate tially different pharmacologic profile. It may be tempting
data to answer this question is lacking, though the avail- to treat otherwise unexplained episodes of rising creati-
able preliminary data is encouraging. Dominguez et al nine levels with high doses of corticosteroids, though the
[23] switched 12 patients with CAN from CI-based ther- improvement in graft function may be transient. Re-
apy to rapamicin and after 6 months reported a signifi- peated courses of “pulse” steroids for patients with pro-
cant decrease in serum creatinine levels (233  34 to gressive CAN should be avoided, as should the mainte-
210  56 mol/L, P  0.05). Five patients developed nance of high baseline doses [25].
pneumonia, however, two with Pneumocystis carinii. The
authors recommended the reintroduction of prophylacic
IMMUNOSUPPRESSIVE MANAGEMENT OFantibiotic therapy [23]. Peraldi et al (abstract P063, 18th
THE END-STAGE TRANSPLANTInternational Congress of the Transplantation Society,
June 2000) in a prospective, non-randomized study of The above discussion has related to the management
of patients with CAN in whom graft function is still re-23 patients with varying degrees of CAN found that graft
function improved when rapamycin was substituted for garded as salvageable. In CAN as in native kidney chronic
Danovitch: Immunosuppression in chronic allograft failure S-71
renal failure, a point is eventually reached when prepara- 2. Consideration should be given to reduction or even
tions for end-stage failure must be made. In the case of discontinuation of CI therapy. Such a therapeutic
CAN, the question of how to manage the immunosup- maneuver requires careful follow-up to screen for
pressive regimen in the abandoned graft must be ad- episodes of deteriorating graft function.
dressed. Ideally, the patient with the failed graft returns 3. Reduction of CI therapy is generally accompanied
to dialysis (or receives another transplant) without the by addition of a non-nephrotoxic immunosuppres-
necessity to remove the failed graft which typically be- sant, though it has not been firmly established that
comes small and fibrotic. Once a decision has been made such addition is necessary. There is most experience
to abandon a graft, it has been my policy to discontinue with MMF in these circumstances, though rapami-
adjunctive immunosuppressive agents (e.g., azathioprine, cin may be an appropriate alternative.
MMF) and to maintain low plasma levels of the CI until 4. Introduction of a new immunosuppressive agent in
dialysis commences at which time they are stopped com- previously immunosuppressed patients has poten-
pletely over several weeks. If a patient is still receiving tially dangerous consequences. Patients should be
corticosteroids, the dose should be minimized and then monitored carefully, and consideration given to
discontinued slowly over several months because the prophylaxis to prevent development of infectious
patient may be adrenally suppressed. During the process complications.
of immunosuppressive withdrawal, the failed graft may 5. High baseline doses of corticosteroids are not indi-
become a source of constitutional symptoms (swelling, cated. “Pulse” steroid therapy may be valuable for
fever, local pain, and hematuria) that require treatment. episodes of deteriorating function, but repeated
In this event, a short course of oral or intravenous cortico- treatment should be avoided. Ideally, use of pulse
steroids may reverse the symptoms and signs. The cortico- steroids in these circumstances should follow histo-
steroid dose, however, should be rapidly returned to its logic confirmation of an element of acute rejection.
baseline level and, if the clinical manifestations return, 6. Since repeated pulse steroid therapy should be
then allograft nephrectomy may be required. The corti- avoided, it is rarely indicated to repeatedly biopsy
costeroid dose should not remain elevated, and other patients with established CAN.
immunosuppressive agents should not be reintroduced. 7. If graft function continues to deteriorate despite
Patients are sometimes reluctant to discontinue immuno- the above measures, plans should be made to pre-
suppression after returning to dialysis for fear of losing pare for ESRD treatment options, and immunosup-
residual graft function and urine output. They should pression should be withdrawn in a stepwise fashion
be persuaded that the risks associated with continued as when dialysis commences.
immunosuppression while on dialysis are not worth the
marginal benefit of the residual function. Correspondence to Gabriel M. Danovitch, M. D., Division of Ne-
phrology, UCLA School of Medicine, Los Angeles, California, USA.
E-mail: gdanovitch@mednet.ucla.edu
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